Thalidomide News and Research

RSS
Thalidomide is a drug that is used to treat multiple myeloma in patients who have just been diagnosed, and a painful skin disease related to leprosy. It is also being studied in the treatment of other types of cancer. Thalidomide belongs to the family of drugs called angiogenesis inhibitors. Also called Thalomid.
ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

ImmunoGen to present IMGN901 clinical data on multiple myeloma at 54th ASH annual meeting

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

Thalidomide effective in treating disabling cough among people with idiopathic pulmonary fibrosis

Viewpoints: Clinton's rousing support for Medicare, health law; Thalidomide and the struggle for an abortion; Arkansas health innovations

Viewpoints: Clinton's rousing support for Medicare, health law; Thalidomide and the struggle for an abortion; Arkansas health innovations

Risky prenatal use of steroid to prevent intersex, tomboys and lesbians

Risky prenatal use of steroid to prevent intersex, tomboys and lesbians

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Multi-center clinical trial results demonstrate safety and efficacy of carfilzomib for multiple myeloma

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

Kyprolis for multiple myeloma receives FDA approval under accelerated approval program

Onyx receives FDA approval for Kyprolis to treat multiple myeloma

Onyx receives FDA approval for Kyprolis to treat multiple myeloma

FDA ODAC votes in favor of Onyx’s Kyprolis

FDA ODAC votes in favor of Onyx’s Kyprolis

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Lenalidomide improves overall survival for patients with multiple myeloma

Lenalidomide improves overall survival for patients with multiple myeloma

Researchers discover connection between early humans and Neanderthals' genome

Researchers discover connection between early humans and Neanderthals' genome

Enrollment complete in Onyx Phase 3 ASPIRE trial for relapsed multiple myeloma

Enrollment complete in Onyx Phase 3 ASPIRE trial for relapsed multiple myeloma

Cereblon protein now holds hope in fight against multiple myeloma

Cereblon protein now holds hope in fight against multiple myeloma

GeneKey launches personalized medicine service for cancer patients

GeneKey launches personalized medicine service for cancer patients

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

Three-drug combination therapy appears to be effective for newly diagnosed MM patients

Celgene announces interim results of REVLIMID study on CLL

Celgene announces interim results of REVLIMID study on CLL